Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343634 | 0.85 | — | — | |
| SCHEMBL30896303 | 0.85 | — | — | |
| SCHEMBL16037715 | 0.85 | — | — | |
| SCHEMBL1077565 | 0.70 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM3CHRM1 | |
| SCHEMBL1077568 | 0.70 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM3CHRM1 | |
| SCHEMBL15578861 | 0.70 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM3CHRM1 | |
| SCHEMBL1077566 | 0.70 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM3CHRM1 | |
| SCHEMBL15520444 | 0.69 | ALDH1A1 (0.42) | CHRM2CHRM4CHRM5CHRM3CHRM1 | |
| SCHEMBL15520446 | 0.69 | ALDH1A1 (0.42) | CHRM2CHRM4CHRM5CHRM3CHRM1 | |
| SCHEMBL15520445 | 0.69 | ALDH1A1 (0.42) | CHRM2CHRM4CHRM5CHRM3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446119-A2 | COMPOSITIONS COMPRISING IPATROPIUM AND XYLOMETAZOLINE FOR TREATMENT OF THE COMMON COLD | Nycomed Danmark ApS (DK) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003024433-A2 | COMPOSITIONS FOR TREATMENT OF COMMON COLD, COMPRISING IPRATROPIUM AND XYLOMETAZOLINE | NYCOMED DANMARK APS (DK) | 2003-03-27 | — | — | WO | disclosed |